Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Cite this article
Drug-Eluting Stents for Emerging Treatment Strategies in Complex Lesions
1 The Sanger Clinic, PA, Carolinas Heart Institute, Charlotte, NC
2 University of North Carolina, Moses H. Cone Memorial Hospital, Greensboro, NC
Rev. Cardiovasc. Med. 2005, 6(S1), 38–47;
Published: 20 January 2005
The use of drug-eluting stents (DES) has rapidly expanded from lower-risk, singlelesion procedures to include a broad spectrum of high-risk patients and complex lesions. For 4 complex patient subgroups, emerging data suggest that DES might offer an advantage for reducing late clinical restenosis. In ST elevation myocardial infarction, early registry reports are promising, with no evidence to date for an increased incidence of subacute stent thrombosis and significant trends for less restenosis. For chronic total occlusions, early, small clinical series show that DES might have unprecedented long-term patency. Initial registries of DES for in-stent restenosis reveal striking reductions in late loss and restenosis, compared with brachytherapy historical controls. The use of DES in saphenous vein graft lesions is increasing, and early registry results show a very acceptable incidence of thromboembolic complications and major adverse cardiac events. Important data regarding much larger groups of these patient cohorts will emerge over the next year, to help guide the broader application of DES in “real-world” practice.
ST elevation myocardial infarction
Chronic total occlusions
Saphenous vein graft